Focusing on Prostate-Specific Membrane Antigen in Precision Diagnosis and Treatment of Prostate Cancer.

Xinyi Ren, Lingling Zhang, Ran An, Hongchen Song, Mingjun Shi, Zhenchang Wang

Abstract readReview

In one paragraph

Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Advances in urology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinyi RenDepartment of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.ORCID 0009-0004-0480-066X

Lingling ZhangDepartment of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.

Ran AnDepartment of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

Hongchen SongDepartment of Surgery, Hebei Medical University, Shijiazhuang 050000, China.

Mingjun ShiDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

Zhenchang WangDepartment of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

Funding

Beijing Key Clinical Specialty Development Project 20240930Beijing Scholars Program No. [2015] 160National Key Clinical Specialty Development Project 20250829The Beijing Physician Scientist Training Project BJPSTP-2025-39The National Natural Science Foundation of China No.82373436

6 · The paper itself

Abstract

Prostate cancer (PCa) is the most common malignant tumor of the male genitourinary system, and its incidence and mortality have shown a marked global increase in recent years. Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein highly expressed in PCa cells, has emerged as a vital molecular target in the field of PCa precision diagnosis and therapy. In recent years, significant advances have been achieved in PSMA-based molecular imaging, radioligand therapy, and the development of novel targeted drugs. This review aims to summarize and critically discuss recent advances in PSMA-targeted molecular imaging, radioligand therapy, and emerging therapeutic strategies, highlighting their roles in precision diagnosis and personalized treatment of PCa. PSMA positron emission tomography/computed tomography (PET/CT) imaging using radionuclides such as

Indexed as

prostate cancerPSMAtargeted imagingtargeted therapy

Identifiers

PMID41751381

DOI10.3390/biomedicines14020482

PMCPMC12938597

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.